Lonza has announced the inclusion of its all-natural prebiotic FiberAid™ in Ultra FiberAid™ capsules from Swanson Health Products. The launch of the Ultra FiberAid™ capsules corresponds to the reintroduction of Swanson’s FiberAid™ powder, now available in a 15 ounce canister.
“The launch of Ultra FiberAid™ capsules provides customers with a trusted source of prebiotic fiber in an easy-to-use complementary formulation to the FiberAid™ powder from Swanson,” said Bryan Rodriguez, Technical Marketing & Scientific Affairs Manager—Lonza. “The inclusion of FiberAid™ in Swanson Ultra is a natural fit, as it offers gut health promoting properties while aligning with Swanson’s standards for a high quality product. We look forward to providing Swanson with high quality ingredients backed by science, and playing an active part in providing industry-leading wellness products to individuals seeking healthy lifestyles.”
A prebiotic fiber with excellent digestive tolerance, Lonza’s FiberAid™ offers food technologists superior technical properties for ease of use in all formulations, including capsule and powder. In Ultra FiberAid™ powder, it remains stable at a low pH and fully soluble as it is readily mixable in beverages. Therefore, end-use customers are afforded the ability to use the product in the manner they prefer.
“We are pleased to be able to introduce a new, convenient capsule form of popular FiberAid™ Larch Tree Arabinogalactan prebiotic fiber,” said Tom Audette, Swanson Health Products’ Director of Product Development. “FiberAid™ is a unique soluble fiber that has a positive influence in promoting healthy microflora, so called “friendly bacteria” in the lower GI tract, with a daily intake of as little as 4.5 grams, taken in divided servings. New FiberAid™ capsules are a convenient way to get the same soluble fiber and prebiotic benefits of the powder while on the go—anytime, anywhere.”
Providing a positive influence on the beneficial microflora of the gut, Lonza’s prebiotic FiberAid™ can increase production of short chain fatty acids while simultaneously reducing ammonia levels in the gut. The gastrointestinal benefits of FiberAid™ are provided without the typical side effects of other dietary fibers, such as gas and bloating. Due to its highly branched structure, FiberAid™ is slowly fermented. FiberAid™ was shown to have a high digestive tolerance at dosages up to 15 g/day in various studies, whereas effective dosages are already achieved at 4.5 g/day. FiberAid™ is a low calorie additive (1.4 kcal/g) and is reported to have no glycemic response.
Swanson Health Products is an industry leader in bringing vitamins directly to consumers at the lowest prices possible. Swanson Health Products, located in Fargo, ND, offers the highest quality vitamins, supplements and natural health care products and is Good Manufacturing Practices certified. Swanson Health Products goes a step beyond its competitors by offering powerful guarantees. All products are backed by a 100% Satisfaction, Money-Back Guarantee and Double the Difference Lowest Price Guarantee. For more information, please visit www.swansonvitamins.com.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, Lonza had sales of CHF 2.69 billion. Further information can be found at www.lonza.com.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.